The association between the OPRM1 A118G polymorphism and addiction in a Turkish population

  • Hülya Türkan Bozok University, Department of Anesthesiology and Reanimation, Yozgat
  • Bensu Karahalil Gazi University, Faculty of Pharmacy Department of Toxicology, Ankara
  • Ela Kadıoğlu Gazi University, Faculty of Pharmacy Department of Toxicology, Ankara
  • Kenan Eren Alcohol and Substance Addiction Treatment and Research Center, Bakirköy State Hospital for Mental and Neurological Diseases, İstanbul
  • Defne Tamar Gürol Alcohol and Substance Addiction Treatment and Research Center, Bakirköy State Hospital for Mental and Neurological Diseases, İstanbul
  • Ali Esat Karakaya Gazi University, Faculty of Pharmacy Department of Toxicology, Ankara
Keywords: alcohol, cannabis, cocaine, ecstasy, hypnotic substances, LSD, opioid, psychiatric disorders, rs1799971, sedatives, μ-opioid receptor

Abstract

Susceptibility to addiction has a complex genetic basis that includes genes associated with the action and metabolism of drugs of abuse. One important gene in that respect is OPRM1, which codes for the μ-opioid receptor and has an important role in mediating the rewarding effects of addiction substances. The aim of our study was to assess the prevalence of the OPRM1 A118G polymorphism (rs1799971) in Turkish population and to investigate its association with opioid and other substance addiction. In addition, we examined the association of rs1799971 in addicted patients who were also diagnosed with psychiatric disorders. The study included 103 patients addicted to opioids, cocaine, ecstasy, alcohol, lysergic acid diethylamide (LSD), cannabis, and sedative/hypnotic substances and 83 healthy volunteers with similar demographic features as controls. rs1799971 polymorphisms were identified with the polymerase chain reaction restriction fragment length polymorphism method (PCR-RFLP). The genotype frequencies were significantly higher in the addicted patients than controls (32.0 % vs 16.9 %, respectively; p=0.027). The prevalence of the G allele was 16.1 % in the addicted group and 8.4 % in the control group (p=0.031). Our study confirmed the association between the rs1799971(G) allele frequency and opioid and other substance addiction, but not with psychiatric disorders.

References

Koob GF, Volkow ND. Neurocircuitr of addiction. Neuropsychopharmacology 2010;35:217–38. doi: 10.1038/npp.2009.110

Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for substance addiction: alcohol and opiates. Am J Drug Alcohol Abuse 2008;34:355–81. doi: 10.1080/00952990802122564

Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci USA 1998;95:9608–13.

Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav 2014;123:25–33. doi: 10.1016/j.pbb.2013.10.018

Beyer A, Koch T, Schröder H, Schulz S, Höllt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004;89:553–60. doi: 10.1111/j.1471-4159.2004.02340.x

Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol addiction in central Sweden. Neuropsychopharmacology 2005;30:417–22. doi: 10.1038/sj.npp.1300598

Kim SA, Kim JW, Song JY, Park S, Lee HJ, Chung JH. Association of polymorphisms in nicotinic acetylcholine receptor alpha 4 subunit gene (CHRNA4), mu-opioid receptor gene (OPRM1), and ethanol-metabolizing enzyme genes with alcoholism in Korean patients. Alcohol 2004;34:115–20. PMID: 15902904

Loh W, Fann CS, Chang YT, Chang CJ, Cheng AT. Endogenous opioid receptor genes and alcohol addiction among Taiwanese Han. Alcohol Clin Exp Res 2004;28:15–9. doi: 10.1097/01.ALC.0000106303.41755.B8

Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D. Mu opioid receptor gene variants: lack of association with alcohol addiction. Mol Psychiatry 1997;2:490–4. doi: 10.1038/sj.mp.4000331

Luo X, Kranzler HR, Zhao H, Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance addiction in European-Americans. Am J Med Gent B Neuropsychiatr Genet 2003;120:97–108. doi: 10.1002/ajmg.b.20034

Troisi A, Frazzetto G, Carola V, Di Lorenzo G, Coviello M, D'Amato FR, Moles A, Siracusano A, Gross C. Social hedonic capacity is associated with the A118G polymorphism of the mu-opioid receptor gene (OPRM1) in adult healthy volunteers and psychiatric patients. Soc Neurosci 2011;6:88–97. doi: 10.1080/17470919.2010.482786

Ding S, Chen B, Zheng Y, Lu Q, Liu L, Zhuge Q. Association study of OPRM1 polymorphisms with Schizophrenia in Han Chinese population. BMC Psychiatry 2013;13:107. doi: 10.1186/1471-244X-13-107

Serý O, Prikryl R, Castulík L, St'astný F. A118G polymorphism of OPRM1 gene is associated with schizophrenia. J Mol Neurosci 2010;41:219–22.

The American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington (DC): American Psychiatric Publishing; 2013.

Karahalil B, Kocabaş NA. hOGG1 SER326CYS genetic polymorphism in a Turkish population. Arch Toxicol 2005;79:377–80. doi: 10.1007/s00204-005-0665-5

Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 2010;1187:184–207. doi: 10.1111/j.1749-6632.2009.05275.x

Kapur S, Sharad S, Sıngha RA. A118g polymorphism in mu opioid receptor gene (OPRM1): association with opiate addiction in subjects of Indian origin. J Integr Neurosci 2007;6:511–22. doi: 10.1142/S0219635207001635

Zhang D, Shao C, Shao M, Yan P, Wang Y, Liu Y, Liu W, Lin T, Xie Y, Zhao Y, Lu D, Li Y, Jin L. Effect of μ-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol Psychiatry 2007;61:1244–51. doi: 10.1016/j.biopsych.2006.07.012

Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J Neurochem 2010;112:486–96. doi: 10.1111/j.1471-4159.2009.06472.x

Sander T, Gscheidel N, Wendel B, Samochowiec J, Smolka M, Rommelspacher H, Schmidt LG, Hoehe MR. Human µ-opioid receptor variation and alcohol addiction. Alcohol Clin Exp Res 1998;22:2108–10. doi: 10.1111/j.1530-0277.1998.tb05923.x

Crowley JJ, Oslin DW, Patkar AA, Gottheil E, DeMaria PA Jr, O'Brien CP, Berrettini WH, Grice DE. A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet 2003;13:169–73. PMID: 12960749

Nikolov MA, Beltcheva O, Galabova A, Ljubenova A, Jankova E, Gergov G, Russev AA, Lynskey MT, Nelson EC, Nesheva E, Krasteva D, Lazarov P, Mitev VI, Kremensky IM, Kaneva RP, Todorov AA. No evidence of association between 118A>G OPRM1 polymorphism and heroin addiction in a large Bulgarian case-control sample. Drug Alcohol Depend 2011;117:62–5. doi: 10.1016/j.drugalcdep.2010.12.026

Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borcgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F. The 118AG polymorphism in the human µ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004;48:1232–9. doi: 10.1111/j.1399-6576.2004.00517.x

Gelernter J, Kranzler H, Cubells J. Genetics of two m opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and substance-dependent subjects. Mol Psychiatry 1999;4:476–83. doi: 10.1038/sj.mp.4000556

Daher M, Costa FMM, Neves FAR. Genotyping the mu-opioid Receptor A118G polymorphism using the real-time amplification refractory mutation system: allele frequency distribution among Brazilians. Pain Pract 2013;13:614–20. doi: 10.1111/papr.12042

Ahmed M, Ul Haq I, Faisal M, Waseem D, Mumtaz MT. Implication of OPRM1 A118G polymorphism in opioids addicts in Pakistan: in vitro and in silico analysis. J Mol Neurosci 2018;65:472–9. doi: 10.1007/s12031-018-1123-1

Szeto CY, Tang NL, Lee DT, Stadlin A. Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 2001;12:1103–6. doi: 10.1097/00001756-200105080-00011

Nagaya D, Ramanathan S, Ravichandran M, Navaratnam V. A118G mu opioid receptor polymorphism among drug addicts in Malaysia. J Integr Neurosci 2012;11:117–22. doi: 10.1142/S0219635212500082

Kim SG, Kim CM, Kang DH, Kim YJ, Byun WT, Kim SY, Park JM, Kim MJ, Oslin DW. Association of functional opioid receptor genotypes with alcohol addiction in Koreans. Alcohol Clin Exp Res 2004;28:986–90. doi: 10.1097/01.ALC.0000130803.62768.AB

Franke P, Wang T, Nothen MM, Knapp M, Neidt H, Albrecht S, Jahnes E, Propping P, Maier W. Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance addiction. Am J Med Genet 2001;105:114–9. PMID: 11424981

Ide S, Kobayashi H, Tanaka K, Ujike H, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Ikeda K, Sora I. Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y Acad Sci 2004;1025:316–24. doi: 10.1196/annals.1316.039

Ginosar Y, Davidson EM, Meroz Y, Blotnick S, Shacham M, Caraco Y. Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic – pharmacodynamic study. Br J Anaesth 2009;103:420–7. doi: 10.1093/bja/aep192

Kumar D, Chakraborty J, Das S. Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:225–30. doi: 10.1016/j.pnpbp.2011.10.018

Arias A, Feinn R, Kranzler R. Association of an Asn40Asp (A118G) polymorphism in the µ-opioid receptor gene with substance addiction: A meta-analysis. Drug Alcohol Depend 2006;27:262–8. doi: 10.1016/j.drugalcdep.2005.11.024

Chen D, Liu L, Xiao Y, Peng Y, Yang C, Wang Z. Ethnic-specific meta-analyses of association between the OPRM1 A118G polymorphism and alcohol addiction among Asians and Caucasians. Drug Alcohol Depend 2012;123:1–6. doi: 10.1016/j.drugalcdep.2011.10.012

Tan EC, Tan CH, Karupathivan U, Yap EP. Mu opioid receptor gene polymorphisms and heroin addiction in Asian populations. Neuroreport 2004;14:569–72. PMID: 12657887

Hoehe MR, Köpke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, Berrettini WH, Church GM. Sequence variability and candidate gene analysis in complex disease: association of µ opioid receptor gene variation with substance dependence. Hum Mol Genet 2000;9:2895–908. doi: 10.1093/hmg/9.19.2895

Published
2019-04-19
How to Cite
1.
Türkan H, Karahalil B, Kadıoğlu E, Eren K, Gürol DT, Karakaya AE. The association between the OPRM1 A118G polymorphism and addiction in a Turkish population. Arh Hig Rada Toksikol [Internet]. 2019Apr.19 [cited 2019Oct.23];70(2). Available from: https://arhiv.imi.hr/index.php/arhiv/article/view/973
Section
Original article